As 2019 draws to a close much has changed since the turn of the millennium in the pathology laboratory. 

The digital age together with ever-more sophisticated microelectronics means that traditional, separately housed, specialist departments such as clinical chemistry and haematology now exist side-by-side in ‘super’ laboratories. 

Many now use sophisticated barcoding systems to track and record test information from patient samples and robotic sample-handling systems can be seen in many large laboratories which provide a tracking pathway for samples to move between sample processing stations, dedicated testing analysers and refrigerated storage systems. 

Hart Biologicals remains at the forefront of the changing requirements needed in the 21st century laboratory by continuing to develop diagnostics tests and reagents suitable for application and use on today’s most sophisticated analysers.

Paul Bates, Sales Manager at Hart Biologicals, said: “One such product is the Fiix Test Kitwhich will now be fully available in the first quarter 2020.

“It offers clinicians involved in the delivery of anticoagulation services the possibility to more effectively control patients using Warfarin as their standard method of ‘blood-thinning’, and also the chance to provide better clinical outcomes and enhanced protection against the occurrence of thrombosis.

“Using the Fiix test, clotting factor levels are balanced so that a change in one particular factor which can occur between testing and dose adjustment is so inconsequential, clinicians can focus directly on controlling more effectively the other factors directly sensitive to the VKA antithrombotic effect. 

The new Fiix test provides a PT/INR result in under two minutes and can be used on all modern-generation automated coagulation systems. 

Paul continued: “With the advancement of machine robotics, tests not previously possible on laboratory coagulometers can now be performed routinely. 

“Platelet function testing historically has been carried out by trained personnel on dedicated semi-automated analysers but fully automated systems such as the Sysmex CS5100* can now perform platelet aggregation testing routinely and the Ristocetin Cofactor test, a parameter which is very important when dealing with patients, often children presenting with the symptoms of von Willebrand Syndrome.”

Hart Biologicals produces a comprehensive range of platelet aggregation reagents for use in light transmittance aggregometry (LTA) which can be used on traditional semi-automated platelet aggregometers or on the fully automated systems, such as the CS5100. 

Paul concluded: “Looking ahead towards the 2020s, expect to see an expanded and more diverse level of testing performed by the routine pathology testing laboratory. 

“The use of modern-day digital communications between patient and test centre will increase dramatically with some analysers already able to report test results direct to a patient’s mobile phone. 

“Future services will offer patients the ability to have more and more routine tests performed next to them, on a ‘near-patient testing’ (NPT) basis or at ‘point of care’ (POC) centres, as exampled by our Thrombistat PT/INR solution negating the need for patients to travel long distances to keep hospital appointments.”

You can find more information on Hart Biologicals’ range of platelet aggregation reagents hereand can find information on Thrombistat here.

*CS5100 system as provided by Sysmex Corporation (HQ: Kobe, Japan)